Long-term results of two unconventional agents in steroid-dependent nephrotic children - PubMed (original) (raw)

Randomized Controlled Trial

. 2005 Oct;20(10):1420-5.

doi: 10.1007/s00467-005-1943-4. Epub 2005 Jul 27.

Affiliations

• PMID: 16047223
• DOI: 10.1007/s00467-005-1943-4

Randomized Controlled Trial

Long-term results of two unconventional agents in steroid-dependent nephrotic children

Ahmed Farouk Donia et al. Pediatr Nephrol. 2005 Oct.

Abstract

Children with steroid-dependent minimal change nephrotic syndrome are prone to serious steroid side effects. Alternative therapies, such as oral cyclophosphamide, may also have serious side effects. We conducted this novel prospective study to compare the long-term efficacies of levamisole and I.V. pulse cyclophosphamide as therapies with potentially fewer side effects. This study included 40 children with idiopathic steroid-dependent minimal change nephrotic syndrome (age 3-15 years; 31 boys and 9 girls). The patients were randomized into two equal groups. One group received levamisole 2.5 mg/kg on alternate days (levamisole group) while the other group received I.V. cyclophosphamide 500 mg/m2/month for six months (cyclophosphamide group). Prednisolone was gradually withdrawn. After stopping treatment, the number of patients that maintained remission was five (25%) in each group at six months, four (20%) versus two (10%) at one year and three (15%) versus one (5%) at two years in the levamisole and cyclophosphamide groups respectively, and one (5%) in each group at three and four years. The overall side effects were mild and both drugs were well tolerated. In view of the results, we recommend trial of levamisole before adopting other therapies with more serious side effects in such patients.

PubMed Disclaimer

Similar articles

• Treatment course of steroid-dependent nephrotic syndrome: emphasized on treatment effect.
  Chen SY, Wu CY, Tsai IJ, Tsau YK. Chen SY, et al. Nephrology (Carlton). 2010 Apr;15(3):336-9. doi: 10.1111/j.1440-1797.2009.01190.x. Nephrology (Carlton). 2010. PMID: 20470303
• Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children.
  Donia AF, Amer GM, Ahmed HA, Gazareen SH, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Donia AF, et al. Pediatr Nephrol. 2002 May;17(5):355-8. doi: 10.1007/s00467-001-0813-y. Pediatr Nephrol. 2002. PMID: 12042893
• Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children.
  Donia AF, Gazareen SH, Ahmed HA, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Donia AF, et al. Nephrol Dial Transplant. 2003 Oct;18(10):2054-8. doi: 10.1093/ndt/gfg300. Nephrol Dial Transplant. 2003. PMID: 13679480
• Management of steroid sensitive nephrotic syndrome: revised guidelines.
  Indian Pediatric Nephrology Group, Indian Academy of Pediatrics; Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, et al. Indian Pediatr. 2008 Mar;45(3):203-14. Indian Pediatr. 2008. PMID: 18367765 Review.
• Management strategy for idiopathic nehprotic syndrome in children.
  Chiu MC. Chiu MC. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;33(1):1-7. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18245896 Review.

Cited by

• Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
  Larkins NG, Hahn D, Liu ID, Willis NS, Craig JC, Hodson EM. Larkins NG, et al. Cochrane Database Syst Rev. 2024 Nov 8;11(11):CD002290. doi: 10.1002/14651858.CD002290.pub6. Cochrane Database Syst Rev. 2024. PMID: 39513526 Review.
• Efficacy and safety of levamisole in childhood nephrotic syndrome: A meta-analysis.
  Bhatt GC, Patel B, Das RR, Malik S, Bitzan M, Mishra NR. Bhatt GC, et al. Indian J Pharmacol. 2023 Jan-Feb;55(1):43-52. doi: 10.4103/ijp.ijp_673_21. Indian J Pharmacol. 2023. PMID: 36960520 Free PMC article. Review.
• Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
  Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Larkins NG, et al. Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD002290. doi: 10.1002/14651858.CD002290.pub5. Cochrane Database Syst Rev. 2020. PMID: 32297308 Free PMC article. Updated.
• Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological Aspects.
  Mühlig AK, Lee JY, Kemper MJ, Kronbichler A, Yang JW, Lee JM, Shin JI, Oh J. Mühlig AK, et al. J Clin Med. 2019 Jun 16;8(6):860. doi: 10.3390/jcm8060860. J Clin Med. 2019. PMID: 31208104 Free PMC article. Review.
• Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials.
  Tan L, Li S, Yang H, Zou Q, Wan J, Li Q. Tan L, et al. Medicine (Baltimore). 2019 May;98(22):e15927. doi: 10.1097/MD.0000000000015927. Medicine (Baltimore). 2019. PMID: 31145359 Free PMC article.

References

1. 1. Acta Paediatr Taiwan. 2000 Mar-Apr;41(2):80-4 - PubMed
2. 1. J Pediatr. 1981 Apr;98(4):561-4 - PubMed
3. 1. Clin Nephrol. 2001 Oct;56(4):289-94 - PubMed
4. 1. Arch Dis Child. 1987 Nov;62(11):1102-6 - PubMed
5. 1. Pediatrics. 1996 Oct;98(4 Pt 1):649-58 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information